EMA Withdrawn: Olanzapine Cipla (previously Olanzapine Neopharma) (olanzapine) — Cipla (EU) Limited

View source ↗

Summary

EMA withdrew Olanzapine Cipla (formerly Olanzapine Neopharma) in the EU; therapeutic areas include schizophrenia and bipolar disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Olanzapine Cipla (olanzapine)

Snippet

Status: Withdrawn. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Cipla (EU) Limited. Decision date: 28/11/2013